Globus Medical (GMED) Prelim. Q4 Revenue Outpaces Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Leerink Partners Raised Price Target on Globus Medical (GMED) Following Preliminary 4Q Results
January 7, 2016 7:20 AM ESTLeerink Partners reiterated an Outperform rating on Globus Medical (NYSE: GMED), and raised the price target to $32.00 (from $31.00), following the company's preliminary 4Q results. Revenues of ~$142.6M were ~$4M above Street. Sales growth y/y did decelerate vs. 3Q but was up against a tougher comp as the TTOT acquisition... More
